Compare MRAM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | ACIU |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.3M | 213.3M |
| IPO Year | 2016 | 2016 |
| Metric | MRAM | ACIU |
|---|---|---|
| Price | $8.00 | $2.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.50 | $10.00 |
| AVG Volume (30 Days) | 238.2K | ★ 241.6K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,642,000.00 | $5,482,957.00 |
| Revenue This Year | $10.80 | N/A |
| Revenue Next Year | $13.42 | $1,022.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.34 | $1.43 |
| 52 Week High | $12.27 | $4.00 |
| Indicator | MRAM | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 44.78 |
| Support Level | $7.48 | $2.70 |
| Resistance Level | $8.42 | $3.13 |
| Average True Range (ATR) | 0.39 | 0.21 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 26.71 | 32.50 |
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.